Citations

Mayo Clinic

Showing 10 of 108572 citations.

Abstract 11536: Cardiac Magnetic Resonance Imaging Paralleled Recurrent Pericarditis Clinical Response to Rilonacept Treatment Over 18 Months: A RHAPSODY Subgroup Analysis
Cremer, Paul , Lin, David , Kwon, Deborah , Jellis, Christine , Clair, JoAnn , Curtis, Allison , Wang, Sheldon, Paolini, John F. , Investigators, for the RHAPSODY, Cremer, Paul C , Brucato, Antonio , Insalaco, Antonella , Luis, Sushil Allen , Klein, Allan L. , Imazio, Massimo , Investigators, for the RHAPSODY

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.11536 Get It

Introduction: Rilonacept treatment in RHAPSODY resolved active pericarditis recurrences, and long-term treatment led to sustained risk reduction. Prior analysis linked greater baseline Late Gadolinium Enhancement (LGE), with more rapid recurrence upon rilonacept suspension after 12 weeks of treatment. Serial cardiac magnetic resonance (CMR) imaging (T2-STIR, LGE) enabled longitudinal assessment for tracking clinical improvement, guiding decision-making, and predicting patient outcomes after treatment cessation. Methods: At the long-term extension (LTE) 18-month decision milestone (18MDM), investigators chose, based on clinical status, to continue rilonacept, suspend rilonacept/observe, or discontinue the LTE. An imaging core lab blinded to clinical data measured pericardial thickness and graded pericardial edema (T2-STIR) and LGE at baseline and 18MDM. Pericarditis recurrence was assessed clinically following rilonacept suspension. Results: Baseline and 18MDM CMRs were available for 13 patients. Reductions in pericardial thickness, T2-STIR, and LGE from baseline to 18MDM while on treatment are provided in Figure . CMRs were obtained in 7/8 patients suspending rilonacept at 18MDM: LGE was none/trace, and T2-STIR was negative; yet, 5/7 (71%) had pericarditis recurrence within 1-4 months of rilonacept suspension despite prophylactic colchicine (n=2). Conclusions: Continued clinical improvement during prolonged rilonacept treatment corresponded with improvement on CMR, including reduced pericardial thickness, resolution of pericardial edema on T2-STIR, and resolution of LGE. Negative/trace LGE at 18MDM while on treatment did not predict absence of pericarditis recurrence upon subsequent rilonacept suspension in this size-limited subgroup. Larger prospective studies examining CMR parameters in guiding RP treatment duration decisions and informing associated clinical outcomes are warranted.
A Response to Partnerships to Facilitate Total Force Fitness
McCarter, Shelly K, Wylam, Mark E. , E Wylam, Mark

Military Medicine | December 18, 2023 | Volume: 189 | Issue: 5-6 | Pages: 132-133

10.1093/milmed/usad478 | PMID 38109734 Get It

Clinicopathologic Findings in Patients With Paraneoplastic Neuropathies and Antibodies Strongly Associated With Cancer
Granger, Andre , Rajnauth, Tina , Lahoria, Rajat , Dubey, Divyanshu , Mills, John R. , Mauermann, Michelle L. , Berini, Sarah E. , Spinner, Robert J. , Dyck, P. James B. , Strong, Michael J. , Mills, J R , Strong, Michael J , Dubey, Divyanshu , Mauermann, Michelle L , Klein, Christopher J.

Neurology | December 18, 2023 | Volume: 102 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000207982 | PMID 38165318 Get It

Contrastive Transfer Learning for Prediction of Adverse Events in Hospitalized Patients
Salehinejad, Hojjat , Meehan, Anne M. , Caraballo, Pedro J. , Borah, Bijan J. , Caraballo, Pedro J , Borah, Bijan J

IEEE Journal of Translational Engineering in Health and Medicine | December 18, 2023 | Volume: 12 | Issue: No issue available | Pages: 215-224

10.1109/jtehm.2023.3344035 | PMID 38196820 Get It

Techniques for restoring optimal spinal biomechanics to alleviate symptoms in Bertolotti syndrome: illustrative case
Brown, Nolan J. , Pennington, Zach , Shahin, Hania, Nguyen, Oanh , Pham, Martin H. , Pennington, Zach

Journal of Neurosurgery: Case Lessons | December 18, 2023 | Volume: 6 | Issue: 25 | Pages: No page available

10.3171/case23467 | PMID 38109726 Get It

BACKGROUND Lumbosacral transitional vertebrae (LSTVs) are congenital anomalies that occur in the spinal segments of L5–S1. These vertebrae result from sacralization of the lowermost lumbar segment or lumbarization of the uppermost sacral segment. When the lowest lumbar vertebra fuses or forms a false joint with the sacrum (pseudoarticulation), it can cause pain and manifest clinically as Bertolotti syndrome. OBSERVATIONS A 36-year-old female presented with severe right-sided low-back pain. Computed tomography was unremarkable except for a right-sided Castellvi type IIA LSTV. The pain proved refractory to physical therapy and lumbar epidural spinal injections, but targeted steroid and bupivacaine injection of the pseudoarticulation led to 2 weeks of complete pain relief. She subsequently underwent minimally invasive resection of the pseudoarticulation, with immediate improvement in her low-back pain. The patient continued to be pain free at the 3-year follow-up. LESSONS LSTVs alter the biomechanics of the lumbosacral spine, which can lead to medically refractory mechanical pain requiring surgical intervention. Select patients with Bertolotti syndrome can benefit from operative management, including resection, fusion, or decompression of the pathologic joint.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Albain, Kathy S. , Yau, Christina , Petricoin, Emanuel F. , Wolf, Denise M. , Lang, Julie E. , Chien, A. Jo , Haddad, Tufia C. , Forero-Torres, Andres , Wallace, Anne M. , Kaplan, Henry G. , Euhus, David , Nanda, Rita , Clark, Amy S. , Godellas, Constantine , Tripathy, Debu , Lu, Janice , Yung, Rachel L. , Wulfkuhle, Julia , Krings, Gregor , Chen, Yunn‐Yi , Potter, David A. , Stringer-Reasor, Erica , Blair, Sarah L. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L. , Sanil, Ashish, Matthews, Jeffrey B. , Melisko, Michelle , Perlmutter, Jane , Symmans, W. Fraser , Veer, Laura J. van’t , Yee, Douglas , Berry, Donald A. , Haddad, Tufia C , Kaplan, Henry , Pusztai, Lajos , Euhus, David , Nanda, Rita , Elias, Anthony D , Clark, Amy S , Godellas, Constantine , Boughey, JC , Isaacs, Claudine , Tripathy, Debasish , Lu, Janice , Yung, Rachel L , Gallagher, Rosa I , Wulfkuhle, Julia D , Brown-Swigart, Lamorna , Krings, Gregor , Chen, Yunn Yi , Potter, David A , Stringer-Reasor, Erica , Blair, Sarah L , Asare, Smita M , Wilson, Amy , Hirst, Gillian L , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L , Berry, Scott , Asare, Adam L , Matthews, Jeffrey B , DeMichele, Angela , Hylton, Nola M. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope S , Symmans, W Fraser , Yee, Douglas , Berry, Donald , Esserman, Laura J , Pusztai, Lajos , Elias, Anthony , Boughey, Judy C. , Isaacs, Claudine , Gallagher, Rosa I. , Swigart, Lamorna Brown , Asare, Adam L. , DeMichele, Angela , Rugo, Hope S. , Esserman, Laura J.

Clinical Cancer Research | December 18, 2023 | Volume: 30 | Issue: 4 | Pages: 729-740

10.1158/1078-0432.ccr-22-2256 | PMID 38109213 Get It

Abstract Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
Remimazolam Sedation and Neuraxial Anesthesia in a Patient with Amyotrophic Lateral Sclerosis Undergoing an Open Colectomy: A Case Report
Nimma, Sindhuja, Gans, Asaf , Wardhan, Richa, Allen, Wesley L. , Allen, Wesley

A&A Practice | December 18, 2023 | Volume: 17 | Issue: 12 | Pages: e01733

10.1213/xaa.0000000000001733 | PMID 38109186 Get It

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving the upper and lower motor neurons. Perioperative management of patients with ALS can be challenging due to the risk of hemodynamic instability, aspiration, and ventilatory failure. We discuss a 58-year-old male patient with ALS who underwent open abdominal surgery under regional anesthesia utilizing a remimazolam infusion for sedation. While various sedation agents have been used successfully in patients with ALS, remimazolam, a new short-acting benzodiazepine with unique pharmacologic properties and reversible anxiolysis, provides amnesia while avoiding ventilatory depression.
Surgically Resected Cardiac Angiosarcoma: Survival Analysis from the National Cancer Database
Rahouma, Mohamed , Baudo, Massimo , Khairallah, Sherif , Lau, Christopher , Gaudino, Mario , Ahmed, Magdy M. El‐Sayed , Kumar, Akshay , Lorusso, Roberto , Mick, Stephanie L., El-Sayed Ahmed, Magdy M , Gaudino, Mario , Lorusso, Roberto , Kumar, Akshay , Rahouma, Mohammed

Journal of Clinical Medicine | December 18, 2023 | Volume: 12 | Issue: 24 | Pages: 7764

10.3390/jcm12247764 | PMID 38137833 Get It

Angiosarcoma is a rare type of soft-tissue sarcoma arising from endothelial cells. It is considered ‘high-grade’ by definition, reflecting its aggressive behavior. We sought to investigate the role of surgery in cardiac angiosarcoma, identify late mortality predictors, and identify interactions with other modalities in its treatment using a national dataset. The 2004–2017 National Cancer Database was reviewed for patients with primary cardiac angiosarcoma. Late mortality predictors were evaluated with Kaplan–Meier curves and Cox regression analysis. Surgery in primary cardiac angiosarcoma was performed in 130 patients (median age 50.5 years; female sex 36.9%). The median follow up was 72.02 months, with a median overall survival (OS) of 14.32 months. In patients treated with surgery in combination with other modalities compared with those treated with surgery alone, median OSs were 17.28 and 2.88 months, respectively (log-rank = 0.018). Older patients (age > 57 years) experienced lower OS compared to those with an age < 57 (log-rank = 0.012). This may be partially explained by the difference in treatment strategies among age groups: those with increasing age, less surgery (p = 0.037), and less chemotherapy (p < 0.001) were chosen. With multivariable Cox regression analysis, age and race other than white or black were identified to be significant independent predictors of late mortality. Cardiac angiosarcoma has poor overall survival, and our findings should further encourage the use of surgery in combination with other therapeutic modalities in treating such an aggressive disease whenever possible.
Age-associated changes in lineage composition of the enteric nervous system regulate gut health and disease
Kulkarni, Subhash , Saha, Monalee , Slosberg, Jared , Singh, Alpana , Nagaraj, Sushma , Becker, Laren , Zhang, Chengxiu , Bukowski, Alicia, Wang, Zhuolun, Liu, Guosheng , Leser, Jenna , Bakhshi, Shriya, Vincent, Elizabeth , Pasricha, Pankaj J. , Singh, Alpana , Nagaraj, Sushma , Kulkarni, Subhash , Kumar, Mithra R. , Anderson, Matthew J , Lewandoski, Mark , Goff, Loyal A.

eLife | December 18, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.88051.2 Get It

The enteric nervous system (ENS), a collection of neural cells contained in the wall of the gut, is of fundamental importance to gastrointestinal and systemic health. According to the prevailing paradigm, the ENS arises from progenitor cells migrating from the neural crest and remains largely unchanged thereafter. Here, we show that the lineage composition of maturing ENS changes with time, with a decline in the canonical lineage of neural-crest derived neurons and their replacement by a newly identified lineage of mesoderm-derived neurons. Single cell transcriptomics and immunochemical approaches establish a distinct expression profile of mesoderm-derived neurons. The dynamic balance between the proportions of neurons from these two different lineages in the post-natal gut is dependent on the availability of their respective trophic signals, GDNF-RET and HGF-MET. With increasing age, the mesoderm-derived neurons become the dominant form of neurons in the ENS, a change associated with significant functional effects on intestinal motility which can be reversed by GDNF supplementation. Transcriptomic analyses of human gut tissues show reduced GDNF-RET signaling in patients with intestinal dysmotility which is associated with reduction in neural crest-derived neuronal markers and concomitant increase in transcriptional patterns specific to mesoderm-derived neurons. Normal intestinal function in the adult gastrointestinal tract therefore appears to require an optimal balance between these two distinct lineages within the ENS.
Radiomics for Differentiation of Pediatric Posterior Fossa Tumors: A Meta-Analysis and Systematic Review of the Literature
Garaba, Alexandru , Ponzio, Francesco , Grasso, E , Brinjikji, Waleed , Fontanella, Marco Maria , Maria, Lucio De , De Maria, Lucio , Fontanella, Marco Maria

Cancers | December 18, 2023 | Volume: 15 | Issue: 24 | Pages: 5891

10.3390/cancers15245891 | PMID 38136435 Get It

Purpose: To better define the overall performance of the current radiomics-based models for the discrimination of pediatric posterior fossa tumors. Methods: A comprehensive literature search of the databases PubMed, Ovid MEDLINE, Ovid EMBASE, Web of Science, and Scopus was designed and conducted by an experienced librarian. We estimated overall sensitivity (SEN) and specificity (SPE). Event rates were pooled across studies using a random-effects meta-analysis, and the χ2 test was performed to assess the heterogeneity. Results: Overall SEN and SPE for differentiation between MB, PA, and EP were found to be promising, with SEN values of 93% (95% CI = 0.88–0.96), 83% (95% CI = 0.66–0.93), and 85% (95% CI = 0.71–0.93), and corresponding SPE values of 87% (95% CI = 0.82–0.90), 95% (95% CI = 0.90–0.98) and 90% (95% CI = 0.84–0.94), respectively. For MB, there is a better trend for LR classifiers, while textural features are the most used and the best performing (ACC 96%). As for PA and EP, a synergistic employment of LR and NN classifiers, accompanied by geometrical or morphological features, demonstrated superior performance (ACC 94% and 96%, respectively). Conclusions: The diagnostic performance is high, making radiomics a helpful method to discriminate these tumor types. In the forthcoming years, we expect even more precise models.